Cargando…

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar

BACKGROUND: Many patients with inflammatory bowel disease (IBD) have transitioned from an infliximab originator to a biosimilar. However, some patients retransition to the originator (i.e. stop biosimilar and reinitiate the originator). Whether this sign of potential unsatisfactory treatment respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meijboom, Rosanne W., Gardarsdottir, Helga, Becker, Matthijs L., Movig, Kris L. L., Kuijvenhoven, Johan, Egberts, Toine C. G., Giezen, Thijs J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496466/ https://www.ncbi.nlm.nih.gov/pubmed/37706094 http://dx.doi.org/10.1177/17562848231197923

Ejemplares similares

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Switching TNFα inhibitors: Patterns and determinants
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
por: Alsamil, Ali M., et al.
Publicado: (2021)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF‐α Inhibitors
por: Minnema, Lotte A., et al.
Publicado: (2020)

Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study
por: Minnema, Lotte A., et al.
Publicado: (2019)

Post‐marketing dosing changes in the label of biologicals
por: Minnema, Lotte A., et al.
Publicado: (2019)

Willingness of patients to use unused medication returned to the pharmacy by another patient: a cross-sectional survey
por: Bekker, Charlotte, et al.
Publicado: (2019)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community
por: Minnema, L. A., et al.
Publicado: (2020)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature
por: Verma, Sanam, et al.
Publicado: (2013)

Head CT is of limited diagnostic value in critically ill patients who remain unresponsive after discontinuation of sedation
por: Balachandran, Jay S, et al.
Publicado: (2009)

Older Patients’ Compliance with Drug Storage Recommendations
por: Vlieland, Nicolaas D., et al.
Publicado: (2018)

Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case–control study
por: Arbouw, Maurits E. L., et al.
Publicado: (2011)

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

The Decline in Geriatric Long Stay Beds: Who Remains?
por: Jenkinson, M. L., et al.
Publicado: (1992)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
por: Lerch, Thomas F., et al.
Publicado: (2019)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
por: Alanaeme, Chibuike J., et al.
Publicado: (2022)

Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar
por: Larson, Jessica, et al.
Publicado: (2023)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

Those who leave and those who stay /
por: Ferrante, Elena
Publicado: (2014)

Survival benefit of coronary-artery bypass grafting accounted for deaths in those who remained untreated
por: Sobolev, Boris G, et al.
Publicado: (2008)

PATIENTS WHO DISCONTINUE DAY HOSPITALISATION - AN ANALYSIS
por: Gopinath, P.S., et al.
Publicado: (1987)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)
por: Derzi, Mazin, et al.
Publicado: (2016)

Advanced assessment through intact glycopeptide analysis of Infliximab’s biologics and biosimilar
por: Kim, Hyejin, et al.
Publicado: (2022)

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
por: Bhat, Shubha, et al.
Publicado: (2020)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6ksd5h1uvm7e20lc5ocons9g7h